caa a22 4500 477058272 CHVBK 20180405111352.0 cr unu---uuuuu 170330e19960201xx s 000 0 eng 10.1007/BF00203783 doi (NATIONALLICENCE)springer-10.1007/BF00203783 Influence of age, frailty and liver function on the pharmacokinetics of brofaromine [Elektronische Daten] [J. Zeeh, W. Bergmann, D. Platt, L. Fuchs, K.-H. Antonin, P. Bieck, F. Degel] Objective: The pharmacokinetics of brofaromine, a selective inhibitor of monoamine oxidase A, was evaluated in 12 frail elderly patients (66-92 y) and 12 healthy volunteers (20-35 y). Methods: Quantitative liver function tests were performed to show whether brofaromine elimination in the elderly could be predicted from noninvasive assessment of CYP1A2 activity (caffeine clearance) or liver plasma flow (sorbitol clearance). Results: In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 μmol*h·l−1, clearance was reduced (5.0 vs. 11.8 l·h−1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h). No significant correlation was observed between hepatic plasma flow and brofaromine clearance (r=0.41, P=0.05), whereas CYP1A2 activity and brofaromine clearance were tightly correlated (r=0.94, P<0.0001). Conclusion: Caffeine clearance, a simple, noninvasive test of CYP1A2 activity, is predictive of brofaromine clearance. Springer-Verlag, 1996 Liver function tests nationallicence elderly nationallicence pharmacokinetics nationallicence geriatrics nationallicence Zeeh J. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut Bergmann W. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut Platt D. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut Fuchs L. Human Pharmacology Institute, Tübingen, Germany aut Antonin K.-H Human Pharmacology Institute, Tübingen, Germany aut Bieck P. Human Pharmacology Institute, Tübingen, Germany aut Degel F. Department of Clinical Chemistry and Laboratory Medicine, Städtisches Klinikum, Nürnberg, Germany aut European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 387-391 0031-6970 49:5<387 1996 49 228 https://doi.org/10.1007/BF00203783 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00203783 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zeeh J. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut NATIONALLICENCE 700 1- Bergmann W. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut NATIONALLICENCE 700 1- Platt D. Chair of Internal Medicine and Gerontology, University Erlangen-Nürnberg, Heimerichstrasse 58, D-90419, Nürnberg, Germany aut NATIONALLICENCE 700 1- Fuchs L. Human Pharmacology Institute, Tübingen, Germany aut NATIONALLICENCE 700 1- Antonin K.-H Human Pharmacology Institute, Tübingen, Germany aut NATIONALLICENCE 700 1- Bieck P. Human Pharmacology Institute, Tübingen, Germany aut NATIONALLICENCE 700 1- Degel F. Department of Clinical Chemistry and Laboratory Medicine, Städtisches Klinikum, Nürnberg, Germany aut NATIONALLICENCE 773 0- European Journal of Clinical Pharmacology Springer-Verlag 49/5(1996-02-01), 387-391 0031-6970 49:5<387 1996 49 228 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer